Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: eico20 who wrote (1617)	1/9/2016 11:30:42 AM
From: eico20	Read Replies (1) \| Respond to of 2026

I like the updates on the FIS slides: ? Prior studies conducted in hard to treat men (PDEi failures) with erectile dysfunction show improvements in IIEF-EF at 300mg Fispemifene daily in conjunction with sildenafil ? Some sub-populations (men with diabetes) showed greater benefit Current Study: ? Dose at 450mg ? Broader patient population (including above populations) ? Lead-in designed to minimize placebo response/exclude placebo responders ? Additional supportive diaries (Sexual Encounter Profiles) the new trial has higher dose and more mild to moderate patients but still some diabetics and more severe patients, and more clarity on the endpoints, libido may be hard to prove, but T level and ED has a very good chance Primary Endpoint: Improvements in Erectile Dysfunction measured by IIEF-EF* ? Key Secondary Endpoints: Change in low libido and serum testosterone with the info now available it appears Repros was reckless and Apri has the clinical work right in line with FDA guidance, hopefully with success.